ArticleDiabetologia2020
miR-409-3p is reduced in plasma and islet immune infiltrates of NOD diabetic mice and is differentially expressed in people with type 1 diabetes.
Article in Diabetologia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 34 citations in OpenAlex.
- Markers Predicting Cure With Combinatorial Treatment in a Mouse Model of Latent Autoimmune Diabetes in Adults.MedComm · 2026Article
- Epigenetic Regulation Involving microRNAs in Diabetes.Biomolecules · 2026Review
- Review
- Preclinical Diagnosis of Type 1 Diabetes: Reality or Utopia.Biomedicines · 2025Review
- microRNAs in Type 1 Diabetes: Roles, Pathological Mechanisms, and Therapeutic Potential.International journal of molecular sciences · 2025Review
- Recent advances in early diagnosis and treatment of T1D with miRNAs.Frontiers in endocrinology · 2025Review
- Importance of Studying Non-Coding RNA in Children and Adolescents with Type 1 Diabetes.Biomedicines · 2024Review
- A set of circulating microRNAs belonging to the 14q32 chromosome locus identifies two subgroups of individuals with recent-onset type 1 diabetes.Cell reports. Medicine · 2024Article
- Circ_0099630 knockdown alleviates lipopolysaccharide-induced injuries of human periodontal ligament cells through the inhibition of TLR4 by releasing miR-409-3p.BMC oral health · 2023Article
- Article
- Immunoregulatory Biomarkers of the Remission Phase in Type 1 Diabetes: miR-30d-5p Modulates PD-1 Expression and Regulatory T Cell Expansion.Non-coding RNA · 2023Article
- Investigating the Function of MicroRNAs in Human Retinal Microvascular Endothelial Cells of Diabetic Retinopathy.Methods in molecular biology (Clifton, N.J.) · 2023Article
- The importance of biomarker development for monitoring type 1 diabetes progression rate and therapeutic responsiveness.Frontiers in immunology · 2023Review
- miRNAs as Biomarkers in Diabetes: Moving towards Precision Medicine.International journal of molecular sciences · 2022Review
- MicroRNA expression profile and identification of novel microRNA biomarkers for metabolic syndrome.Bioengineered · 2021Article
- Protocol to analyze circulating small non-coding RNAs by high-throughput RNA sequencing from human plasma samples.STAR protocols · 2021Article
- MicroRNAs, Parkinson's Disease, and Diabetes Mellitus.International journal of molecular sciences · 2021Review
- Extracellular Vesicles in Immune System Regulation and Type 1 Diabetes: Cell-to-Cell Communication Mediators, Disease Biomarkers, and Promising Therapeutic Tools.Frontiers in immunology · 2021Review
- MicroRNA Expression in the Aqueous Humor of Patients with Diabetic Macular Edema.International journal of molecular sciences · 2020Article
- Presumption of innocence for beta cells: why are they vulnerable autoimmune targets in type 1 diabetes?Diabetologia · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aims/hypothesisMicroRNAs (miRNAs) are a novel class of potential biomarkers emerging in many diseases, including type 1 diabetes. Here, we aim to analyse a panel of circulating miRNAs in non-obese diabetic (NOD) mice and individuals with type 1 diabetes.
methodsWe adopted standardised methodologies for extracting miRNAs from small sample volumes to evaluate a profiling panel of mature miRNAs in paired plasma and laser-captured microdissected immune-infiltrated islets of recently diabetic and normoglycaemic NOD mice. Moreover, we validated the findings during disease progression and remission after anti-CD3 therapy in NOD mice, as well as in individuals with type 1 diabetes.
resultsPlasma levels of five miRNAs were downregulated in diabetic vs normoglycaemic mice. Of those, miR-409-3p was also downregulated in situ in the immune islet infiltrates of diabetic mice, suggesting an association with disease pathogenesis. Target-prediction tools linked miR-409-3p to immune- and metabolism-related signalling molecules. In situ miR-409-3p expression correlated with insulitis severity, and CD8 CONCLUSIONS/
interpretationWe propose that miR-409-3p may represent a new circulating biomarker of islet inflammation and type 1 diabetes severity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.